Reuters logo
4 years ago
Sangamo Biosciences to develop blood disorder drugs with Biogen
January 9, 2014 / 12:30 PM / 4 years ago

Sangamo Biosciences to develop blood disorder drugs with Biogen

Jan 9 (Reuters) - Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders.

Sangamo shares rose about 8 percent to $14.74 in premarket trading.

Biogen will pay Sangamo $20 million upfront, and use Sangamo's gene-based technology to develop drugs targeting sickle cell disease and beta-thalassemia.

Sangamo will also be eligible for additional payments of about $300 million in milestones, as well as double digit royalties on product sales.

The company will be responsible for research and development activities for the first proof-of-concept study for beta-thalassemia.

Biogen will pay for research costs incurred by Sangamo and market drugs developed during the collaboration. (Reporting By Vrinda Manocha in Bangalore; Editing by Joyjeet Das)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below